Trial · NCT06974786
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786, Phase 2, Recruiting, SCRI Development Innovations, LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma. Trials, record NCT06974786. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06974786
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- NCT number
- NCT06974786
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- SCRI Development Innovations, LLC
- Conditions
- Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
- Interventions
- Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
- First posted
- 2025-05-16
- Last updated
- 2026-06-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of MRD negativity after completion of Maintenance 1 | At 60 weeks | Rate of participants with MRD negativity (defined as \<10-5) after completion of the Maintenance 1 portion of the study. |
| Secondary | Rate of sustained MRD negativity after completion of Consolidation and Maintenance 1 or after completion of Maintenance 1 and Maintenance 2 | 60 weeks or 108 weeks, respectively | Rate of participants with MRD negativity (defined as \<10-5) after completion of the Consolidation and Maintenance 1 (negative at both timepoints) or after completion of Maintenance 1 and Maintenance 2 (negative at both timepoints). |
| Secondary | Event-free survival (EFS) | 5 years | Median time from randomization until event using Kaplan-Meier estimates. Event is defined as death, disease progression as defined by the International Myeloma Working Group standard response criteria, initiation of alternative regimen (including Arms A1 or B1 due to MRD positivity after Maintenance 1) or resurgence of MRD (i.e. MRD becoming ≥10-5 after prior negative result \<10-5). |
| Secondary | Incidence of adverse events | 5 years | Number of participants with adverse events as assessed by common terminology criteria for adverse events (CTCAE) v5.0. |
| Secondary | Rate of MRD negativity at any point in Arm A1 | 72 weeks and 120 weeks, respectively | Rate of participants with MRD negativity (defined as \<10-5) after completion of ASCT or after maintenance treatment. |
| Secondary | Rate of MRD negativity at any point in Arm B1 | 72 weeks and 120 weeks, respectively | Rate of participants with MRD negativity (defined as \<10-5) after completion of consolidation with elranatamab and daratumumab or after completion of maintenance with elranatamab and daratumumab. |
| Secondary | International Myeloma Working Group (IMWG) Frailty Index- Comparison in participant report outcomes from baseline to end of treatment | 4 years | Comparison in participant report outcomes from baseline to end of treatment. Frailty score (range 0-5) and categorizes participants into fit (score = 0), intermediate-fit (score = 1) and frail (score ≥ 2). |
| Secondary | European Organisation for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire (QLQ)-C30- MY20 module- Comparison in participant report outcomes from baseline to end of treatment | 4 years | Quality of life questionnaire. Version QLQ-C30. Disease specific module MY-20. Scores are based on a 0-100 scale, with higher scores generally indicating better health-related quality of life. |
| Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS)- Comparison in participant report outcomes from baseline to end of treatment | 4 years | Patient-reported overall health and quality of life questionnaire. Global 10 version. The possible score ranges from 0 to 20 points in each case. 0 points represent the patient's most severe physical and/or mental impairment, while 20 points represent the best possible state of health. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06974786
GET https://conductscience.org/api/trials/v1/NCT06974786/registered